会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 41. 发明授权
    • 뮤신이 없는 배지에서 배양한 아커만시아 뮤시니필라 균주 또는 이의 배양액을 유효성분으로 함유하는 대사성 질환의 예방, 개선 또는 치료용 조성물
    • 阿克尔在不存在粘蛋白只介质氰基亩光亮支柱应变或预防代谢性疾病的组合物,改善或治疗其含有作为活性成分的培养液的培养
    • KR101809172B1
    • 2017-12-14
    • KR1020170087540
    • 2017-07-11
    • 한국생명공학연구원
    • 김병찬이철호노정란김경심김명희김용훈이상준장동호최동희황정환서윤정이인복최영근최정현
    • A61K35/74A23L33/135A23K10/16
    • 본발명은뮤신이없는배지에서배양한아커만시아뮤시니필라균주또는이의배양액을유효성분으로함유하는대사성질환의예방또는치료용약학적조성물및 건강기능식품조성물에관한것으로, 본발명의장내미생물인아커만시아뮤시니필라() 균주는고지혈증, 지방간, 비만및 당뇨를포함한대사성질환을개선시키므로, 대사성질환의예방이나치료를위한식품, 의약품또는사료로유용하게사용될수 있다. 특히, 본발명에서는뮤신(mucin)이있는배지에서배양한경우보다뮤신이없는배지에서배양한아커만시아뮤시니필라균주를경구투여(in vivo) 했을때, 고지방식이로유도된마우스모델에서발생한고지혈증, 지방간, 비만및 고혈당의개선효과가현저한것을확인하였기때문에, 본발명을통해아커만시아뮤시니필라균주의효능을극대화하기위한특정배양배지조성및 최적화된절대혐기적배양방법을개발함으로써, 본발명은관련산업에매우유용하다.
    • 本发明涉及的代谢紊乱的物质的药物组合物和含有该城市仅标记在不存在粘蛋白的培养基作为活性成分,本发明的肠道微生物群落的孵育的AMU光亮支柱应变或培养健康功能食品组合物,用于预防或治疗 INAH增加仅当AMU光亮支柱()的菌株可以是高脂血症,脂肪肝疾病,肥胖症,而且由于改善代谢性疾病包括糖尿病,食品为代谢性疾病,药品或饲料的预防或治疗。 特别地,当口服施用至AMU光亮支柱应变本发明中,粘蛋白时(粘蛋白)当只有一个标记比不存在与在小鼠模型中产生的(体内),高脂血症的培养基中的粘蛋白培养基培养hangyeongwoo的孵育由其衍生的脂肪 ,肝脏,因为它证实了改善肥胖和高血糖,通过使用本发明的显着效果制定了具体的培养基组合物和优化的绝对厌氧培养方法以最大化AMU晶灵支柱应变的功效时仅该标记时,该 本发明对相关行业非常有用。
    • 46. 发明授权
    • 필발로부터 얻은 지방산 생합성 효소 저해용 활성분획조성물
    • 필발로터얻은지방산생합성효소저해용활성분획조성물
    • KR100390766B1
    • 2003-07-10
    • KR1020010005469
    • 2001-02-05
    • 한국생명공학연구원
    • 오원근안종석김보연민태익안순철강대욱이명선이철호현병화김명수
    • A61K36/67
    • PURPOSE: An active composition showing a specific inhibiting activity against Lepr¬(db)/Lepr¬(db) as a model animal causing obesity by the abnormality of a leptin receptor, obtained from a Piper Longum extract is provided which has an excellent effect on inhibiting fatty acid synthesis, preventing and treating obesity, reducing blood sugar and inhibiting fatty liver. CONSTITUTION: Piper Longum is ground and extracted as much as 3 to 10 times to an alcohol aqueous solution 3 times, a concentrate is suspended in as much as 50 to 100 times by volume of distilled water, passed through diionic HP-20 resin, and a nonactive fraction is eluted with 30% methanol. The absorbed active fraction is eluted 10 to 20 times with acetone and concentrated to give an extract, which is suspended in 10 to 100 times with distilled water and extracted with chloroform and ethyl acetate to give an extract, which is suspended in 1 to 2 times with distilled water.
    • 目的:提供了一种活性组合物,该活性组合物显示出作为通过由Pi Long提取物获得的瘦蛋白受体异常而导致肥胖的模型动物Lepr(db)/ Lepr(no)(db)的特异性抑制活性,其对 抑制脂肪酸合成,预防和治疗肥胖症,降低血糖和抑制脂肪肝。 构成:将Piper Longum粉碎并提取3至10倍于醇水溶液3次,浓缩物悬浮于50至100倍体积的蒸馏水中,通过diionic HP-20树脂,并且 用30%甲醇洗脱非活性部分。 吸收的活性部分用丙酮洗脱10至20次,浓缩得到提取物,用蒸馏水将其悬浮10至100倍,用氯仿和乙酸乙酯提取,得到提取物,将其悬浮1至2次 用蒸馏水。
    • 47. 发明公开
    • 희첨으로부터 얻은 단백질 타이로신 탈인산화 효소 1B저해용 활성분획물
    • 用于抑制从SIEGESBECKIA SPP获得的蛋白酪氨酸磷酸化酶1B的活性物质。
    • KR1020030015575A
    • 2003-02-25
    • KR1020010049362
    • 2001-08-16
    • 한국생명공학연구원
    • 안종석오원근김보연안순철강대욱이명선배은영이철호오구택김명수
    • A61K36/28A61P3/10
    • PURPOSE: Provided is an active fraction containing a Siegesbeckia spp. extract which exhibits an excellent effect on inhibition of protein tyrosine phosphatase 1B and reduction of blood sugar levels in Lepr ¬db/Lepr ¬db mouse as a model animal causing type II diabetes and obesity by abnormality of a leptin receptor. It is effective in prevention and treatment of diabetes. CONSTITUTION: Siegesbeckia spp. is extracted in an aqueous alcohol solution and suspended in distilled water. An inactive fraction is removed therefrom with hexane and the aqueous solution, whose inactive fraction is removed, is extracted with chloroform. Thereafter, the concentrate is loaded on a silica gel to dissolve an active matter with a hexane/ethyl acetate solvent, followed by Sephadex LH-20 to dissolve an inactive matter with a chloroform/hexane solvent. And then an active material is extracted, freeze-dried and purified.
    • 目的:提供含有Siegesbeckia spp的活性成分。 提取物,其对Leprðdb/ Leprðdb小鼠的蛋白酪氨酸磷酸酶1B的抑制和血糖水平的降低具有优异的效果,作为通过瘦素受体异常引起II型糖尿病和肥胖的模型动物。 有效预防和治疗糖尿病。 构成:Siegesbeckia spp。 在醇水溶液中萃取并悬浮于蒸馏水中。 用己烷除去无活性级分,除去非活性级分的水溶液用氯仿萃取。 此后,将浓缩物装载在硅胶上,用己烷/乙酸乙酯溶剂溶解活性物质,接着用Sephadex LH-20,用氯仿/己烷溶剂溶解惰性物质。 然后提取活性物质,冷冻干燥并纯化。
    • 49. 发明公开
    • 딥터로카퍼스 투버큘라투스 추출물 또는 이의 분획물을 함유하는 대사성 질환 예방 및 치료용 약학적 조성물
    • 含有二甲双胍的提取物或组分用于预防或治疗代谢疾病的药物组合物
    • KR1020140048798A
    • 2014-04-24
    • KR1020130115388
    • 2013-09-27
    • 한국생명공학연구원
    • 이현선김문옥서지희이철호한아름오세량
    • A61K36/185A61K36/18A61P3/04A61P3/10
    • The present invention relates to a pharmaceutical composition containing Dipterocarpus tuberculatus extract or a fraction thereof as an effective ingredient for preventing or treating metabolic diseases. The Dipterocarpus tuberculatus extract or the fraction thereof according to the present invention effectively restrains the activity of glycerol-3-phosphate (GPAT) that induces metabolic diseases, inhibits the biosynthesis of neutral fats in hepatic cells, restrains the accumulation of fats in the hepatic cells, increases glucose uptake in skeletal muscle cells, and drops in blood sugar level in an oral glucose tolerance test (OGTT) of animals. The composition including the Dipterocarpus tuberculatus extract or the fraction thereof according to the present invention as an effective ingredient may be usefully used for preventing and treating metabolic diseases such as obesity, type 2 diabetes, insulin resistance, hepatic steatosis and non-alcoholic fatty liver.
    • 本发明涉及一种药物组合物,其含有结核桃提取物或其一部分作为预防或治疗代谢性疾病的有效成分。 根据本发明的二仙子提取物或其级分有效地抑制了诱导代谢疾病的甘油-3-磷酸(GPAT)的活性,抑制肝细胞中的中性脂肪的生物合成,抑制了肝细胞中脂肪的积累 ,增加了骨骼肌细胞中的葡萄糖摄取,并且在口服葡萄糖耐量试验(OGTT)中降低了血糖水平。 作为有效成分的根据本发明的二叉戟提取物或其成分的组合物可以有效地用于预防和治疗诸如肥胖症,2型糖尿病,胰岛素抵抗,肝脂肪变性和非酒精性脂肪肝等代谢疾病。